Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TT-004
- Development stage
- Preclinical
- Lead developer
- Teon Therapeutics
- Modality
- Small Molecules
- Administration
- Unspecified Route
01
Overview
TT-004 is a small molecule drug candidate with at least two distinct entities reported under this code name. One version of TT-004 is being developed by Teon Therapeutics as an antineoplastic agent targeting a G protein-coupled receptor (GPCR) antagonist mechanism for cancer indications. Another version of TT-004 (by Ting Therapeutics) is in preclinical development for nervous system and otorhinolaryngologic diseases, specifically hearing loss; however, its precise target and mechanism are not disclosed. Both versions are new molecular entities and remain in preclinical or early clinical development stages[1][3].
- Other names
- TT 004TT004TT-004TT-004(Ting Therapeutics)
Beyond the preview
Go deeper on TT-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TT-004.